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Nursing Care 
Insulin resistance due to obesity 
Chasidy Crist BSN, RN 
Introduction 
Diabetes is defined as a common metabolic 
disorder where hyperglycemia or elevated 
glucose levels are prevalent (Shah & Vella, 2014). 
The most common form of diabetes is type two 
diabetes (T2DM) and effects around 9.3% of the 
population in the United States (Cornell, 2015, p. 
631). The pathophysiology of this disease includes 
involvement from the pancreas, liver, skeletal 
muscle, adipose tissue, gastrointestinal tract, brain, 
and kidneys. Hyperglycemia is high blood sugar 
levels that effects multiple organs (Rymaszewski & 
Breakwell, 2013). Protocols are developed to allow 
nurses to identify and treat hyper/hypoglycemia. 
Patient education is a direct impact of the long 
term effects of this illness. Maintaining a blood 
glucose level of 80-110 for hospitalized patients is 
a key component to faster recovery and less 
hospital days (Dumont & Bourguignon, 2012). 
Obesity is directly related to an increase of diabetes 
in the United States. There are many risk factors for 
T2DM including age, race, pregnancy, stress, 
genetics, and obesity. Obesity leads to a decreased 
ability to produce insulin properly and 
development of T2DM. Diabetes is largely 
preventable by maintaining a healthy weight with 
proper diet and exercise.  
  
Pathophysiology of Diabetes 
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Underlying 
Pathophysiology 
 
Insulin resistance T2DM is directly related to 
obesity. Obesity is due to a difference in the amount 
of energy used verses the amount of food eaten. The 
excessive accumulation of adipose tissue can lead to 
obesity and increased inflammation. Adipose tissue 
is where energy is stored and released. Energy is in 
the form of triglycerides. Adipose sites contain 
multiple cell types such as adipocytes, 
preadipocytes, endothelial cells, and immune cells.  
An excessive amount of fat accumulation promotes 
the release of free fatty acids. Hypertrophy or 
enlargement of adipocytes are associated with 
obesity and play an important role in insulin 
resistance. When energy is needed, such as with 
exercise, the triglycerides are mobilized by lipolysis 
and FFA’s are released. The FFA’s are then 
transported to other tissues and used as energy. 
FFA’s are a key link to obesity and metabolic 
disorders such as insulin resistance T2DM (Jung & 
Choi, 2014). FFA’s enter the liver portal, serve as a 
ligand-toll receptor, and produce cytokines and 
macrophages that cause inflammation.  
The pathophysiology of Diabetes involves multiple organs. The 
pancreas is responsible for the B-cell function and insulin secretion. 
People that have impaired glucose tolerance may have lost 80% of 
their b-cell function early on in the disease (Cornell, 2015). A decline 
in B-cell function is due to elevated glucose levels and free fatty 
acids, age, genetics, poor diet and lack of exercise. The liver is the 
main organ where glucose is produced. Diabetic patients have an 
overproduction of glucose by the liver (Cornell, 2015).). 
Overproduction of hepatic glucose comes from gluconeogenesis 
and glycogenolysis. Gluconeogenesis is the formation of glucose 
from sources other than carbohydrates. The process takes place in 
the liver. Glucogenolysis is the process of glycogen forming into 
glucose. Glucose is needed for energy and metabolic function. The 
muscles aid in disposal of exogenous glucose and transportation of 
glucose to the skeletal muscles. Patients with T2DM have a 
resistance to the action of insulin in the muscles due to lack of 
physical activity. This causes a decrease in the glucose uptake, which 
further leads to hyperglycemia. The adipose tissue become resistant 
to insulin which leads to an excess amount of free fatty acids (FFA) 
in the blood stream. Chronic high levels of FFA’s stimulate 
gluconeogenesis. “Brown fat” is a very metabolically active adipose 
tissue found in patients with weight control concerns (Cornell, 2015. 
Newer research suggest that brown fat may play an important role 
in how the body metabolizes glucose and energy production. Insulin 
crosses the blood brain barrier and can become resistant over time. 
Leptin is a hormone that acts on the hypothalamus by controlling 
food intake and energy (Cornell, 2015). Many patients with T2DM 
are obese and have high levels of circulating leptin. Amylin is a 
peptide that is secreted from B-cells along with insulin. It works to 
slow digestive emptying and reduce glucagon release.  
Since patients with T2DM have a decrease production of B-cells, 
amylin secretion is also decreased. Glucagon-like peptide (GLP-1) 
and glucose-dependent insulin tropic polypeptide (GIP) are released 
by the gastrointestinal tract and stimulate the release of insulin. 
There is a decline in production of GLP-1 and GIP, which results in 
hyperglycemic effects. The kidneys work to filter the glucose. When 
the glucose levels exceed the renal threshold (180ml/dL) the glucose 
is excreted into the urine. Patients with T2DM are able to absorb 
glucose by the kidneys and return it to circulate in the body causing 
hyperglycemia (Cornell, 2015). 
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There is no cure for T2DM. Physicians, nurse 
practitioners, and nurses play a key role in the education 
about this disease, including how to prevent and manage 
T2DM. Oral medication and insulins are effective 
treatment options, but ultimately controlling the glucose 
levels by diet and exercise help decrease the severity of the 
illness. Diabetes can affect many other organs including 
your heart, kidneys, brain, eyes, and vascular system. 
Optimal glucose control is achieved by early diagnosis and 
intense treatment.  Diet and exercise play a key role in 
decreasing the risk of developing T2DM. Understanding 
how to keep a body mass index below30 kg/m2  will help 
with insulin resistance.  
Conclusion Significance of Pathophysiology 
The first line of treatment for a newly diagnosed T2DM is metformin and 
exercise (Brunton, 2010). Unfortunately, side effects of Metformin include 
hypoglycemia and weight gain. According to Dumont and Bourguignon, the 
insulin dosage calculator improves the patients’ blood glucose measurements, as 
well as increasing nurse’s satisfaction by decreasing amount of workload needed 
for diabetic patient control (Dumont & Bourguignon, 2012). Best practice shows 
that dosing insulin based on weight, carbohydrates, and blood glucose improves 
overall control. Scientist are continuing to understand what pharmacological and 
non-pharmacological approaches are best for this disease.  A recent research 
noted that an increased body mass index (BMI) directly correlated with insulin 
resistance and is due to the increase in abdominal adiposity (Cummings, Dubose, 
Imai, & Collier, 2009). It is suggested that a low cardiorespiratory fitness will help 
patients decrease their BMI and abdominal adiposity. Caring for patients with 
T2DM requires close monitoring, great glycemic control, encouraging exercise, 
and addressing the underlying cause of hyperglycemia (Casey, 2011). The 
hemoglobin (A1C) should be monitored in diabetic patients at least two times a 
year if levels are under control, and up to four times a year for patients with 
uncontrolled diabetes (Cornell, 2015). Diabetes signs and symptoms include: 
polyuria (excessive amounts of urine), polydipsia (excessive thirst), polyphagia 
(excessive hunger), and fatigue (Casey, 2011)  
 
Insulin resistance is a decreased ability for the tissues such as adipose 
tissue to react to insulin. Insulin is activated by binding to the cell receptor 
causing phosphorylation of the insulin receptor substrate (IRS) proteins that 
signal two pathways. These pathways aid in the transport of glucose to the 
plasma membrane, resulting in hypertrophic adipose tissue. Obesity produces 
extracellular concentrations of lipids and abundance accumulation of 
macrophages in adipose tissue which causes insulin resistance. Inflammation, 
cytokines and other bioactive substances are linked to obesity induced insulin 
resistance. The significant impact of obesity has nearly doubled from 1980 to 
2008 (Jung & Choi, 2014). This fast growing concern with obesity related 
insulin resistance leads to the development of T2DM along with other health 
conditions such as heart disease, stroke, retinopathy, encephalopathy, 
neuropathy, and peripheral vascular disease (Jung & Choi, 2014).  
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Diabetes Reveals Potential Therapy (2015).  
